Table 9.
Predictive risk of CCA recurrence in early stage patients using soluble CD44, CD44v6, CD44v8-10, and EpCAM
| Comparative prediction | Post-operative recurrence | |||
|---|---|---|---|---|
| OR crude | p (95% CI) | OR adjusted | p (95% CI) | |
| CD44 ≥ 0.505 vs. < 0.505 | 3.67 | 0.022 (1.207–11.183) | 3.62 | 0.031 (1.126–11.66) |
| CD44v6 ≥ 0.814 vs. < 0.814 | 4.64 | 0.008 (1.503–14.346) | 4.98 | 0.009 (1.504–16.473) |
| CD44v8-10 ≥ 0.713 vs. < 0.713 | 6.55 | 0.002 (2.029-21.116) | 5.92 | 0.004 (1.779-19.706) |
| EpCAM ≥ 0.814 vs. < 0.814 | 6.91 | 0.001 (2.147–22.202) | 6.23 | 0.003 (1.867–20.793) |
CD44 cluster of differentiation 44, CD44v CD44 variant, EpCAM epithelial cell adhesion molecules, OR odds ratio, OR adjusted odds ratio adjusted for age and sex statistical analysis, 95% CI 95% confidence interval